206 related articles for article (PubMed ID: 33636038)
1. Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX-Padua.
Robinson MM; George LA; Carr ME; Samelson-Jones BJ; Arruda VR; Murphy JE; Rybin D; Rupon J; High KA; Tiefenbacher S
J Thromb Haemost; 2021 May; 19(5):1212-1218. PubMed ID: 33636038
[TBL] [Abstract][Full Text] [Related]
2. Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study.
Bowyer AE; Hillarp A; Ezban M; Persson P; Kitchen S
J Thromb Haemost; 2016 Jul; 14(7):1428-35. PubMed ID: 27107268
[TBL] [Abstract][Full Text] [Related]
3. Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one-stage clotting assays.
Horn C; Négrier C; Kalina U; Seifert W; Friedman KD
J Thromb Haemost; 2019 Jan; 17(1):138-148. PubMed ID: 30418692
[TBL] [Abstract][Full Text] [Related]
4. Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol.
Tiefenbacher S; Bohra R; Amiral J; Bowyer A; Kitchen S; Lochu A; Rosén S; Ezban M
J Thromb Haemost; 2017 Oct; 15(10):1901-1912. PubMed ID: 28772338
[TBL] [Abstract][Full Text] [Related]
5. Overestimation of N-glycoPEGylated factor IX activity in a one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX.
Rosén P; Rosén S; Ezban M; Persson E
J Thromb Haemost; 2016 Jul; 14(7):1420-7. PubMed ID: 27169618
[TBL] [Abstract][Full Text] [Related]
6. Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity.
Sommer JM; Buyue Y; Bardan S; Peters RT; Jiang H; Kamphaus GD; Gray E; Pierce GF
Thromb Haemost; 2014 Nov; 112(5):932-40. PubMed ID: 25144892
[TBL] [Abstract][Full Text] [Related]
7. A computer-based model to assess costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assays.
Kitchen S; Blakemore J; Friedman KD; Hart DP; Ko RH; Perry D; Platton S; Tan-Castillo D; Young G; Luddington RJ
J Thromb Haemost; 2016 Apr; 14(4):757-64. PubMed ID: 26748742
[TBL] [Abstract][Full Text] [Related]
8. Field Study and Correlative Studies of Factor IX Variant FIX-R338L in Participants Treated with Fidanacogene Elaparvovec.
Pittman DD; Carrieri C; Soares H; McKay J; Tan CY; Liang JZ; Rakhe S; Marshall JC; Murphy JE; Gaitonde P; Rupon J
Thromb Haemost; 2024 Jun; ():. PubMed ID: 38863155
[TBL] [Abstract][Full Text] [Related]
9. Differences in wild-type- and R338L-tenase complex formation are at the root of R338L-factor IX assay discrepancies.
Foley JH; Shehu E; Riddell A; Gray E; Goodale A; Yu IM; Verhoef D; Little J; Shattock D; Kitchen S; Chowdary P; Corbau R; Nathwani AC
Blood Adv; 2023 Feb; 7(3):458-467. PubMed ID: 35839077
[TBL] [Abstract][Full Text] [Related]
10. Real-world assay variability between laboratories in monitoring of recombinant factor IX Fc fusion protein activity in plasma samples.
Sommer JM; Sadeghi-Khomami A; Barnowski C; Wikén M; Willemze AJ
Int J Lab Hematol; 2020 Jun; 42(3):350-358. PubMed ID: 32202380
[TBL] [Abstract][Full Text] [Related]
11. [Factor IX assays in treated hemophilia B patients].
Pouplard C; Jeanpierre E; Lasne D; Le Cam Duchez V; Eschwege V; Flaujac C; Galinat H; Harzallah I; Proulle V; Smahi M; Sobas F; Ternisien C; Toulon P; Voisin S; Nougier C;
Ann Biol Clin (Paris); 2019 Feb; 77(1):41-52. PubMed ID: 30799297
[TBL] [Abstract][Full Text] [Related]
12. Treatment of a Hemophilia B Mouse Model with Platelet-Targeted Expression of Factor IX Padua.
Li B; Wu Z; Xu W; Han W; Liu J; Wang D; Zhang G
Hum Gene Ther; 2021 May; 32(9-10):506-516. PubMed ID: 33764159
[TBL] [Abstract][Full Text] [Related]
13. Calibration of the WHO 5th IS for Blood Coagulation Factor IX, Concentrate and Ph. Eur. Human Coagulation Factor IX Concentrate Biological Reference Preparation Batch 3 and investigation of the suitability of an IS as potency standard for purified full-length recombinant FIX.
Gray E; Hogwood J; Dougall T; Rigsby P; Matejtschuk P; Terao E
Pharmeur Bio Sci Notes; 2021; 2021():26-68. PubMed ID: 33783349
[TBL] [Abstract][Full Text] [Related]
14. AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice.
Crudele JM; Finn JD; Siner JI; Martin NB; Niemeyer GP; Zhou S; Mingozzi F; Lothrop CD; Arruda VR
Blood; 2015 Mar; 125(10):1553-61. PubMed ID: 25568350
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B.
Shah J; Kim H; Sivamurthy K; Monahan PE; Fries M
Curr Med Res Opin; 2023 Feb; 39(2):227-237. PubMed ID: 36285399
[TBL] [Abstract][Full Text] [Related]
16. Clinical Implications of Discrepancy between One-Stage Clotting and Chromogenic Factor IX Activity in Hemophilia B.
Schmidt DE; Truedsson Å; Strålfors A; Hojbjerg JA; Soutari N; Holmström M; Ranta S; Letelier A; Bowyer A; Ljung R; Antovic J; Bruzelius M
Thromb Haemost; 2024 Jan; 124(1):32-39. PubMed ID: 37494968
[TBL] [Abstract][Full Text] [Related]
17. Recombinant factor IX: discrepancies between one-stage clotting and chromogenic assays.
Wilmot HV; Hogwood J; Gray E
Haemophilia; 2014 Nov; 20(6):891-7. PubMed ID: 24800651
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy for hemophilia B using CB 2679d-GT: a novel factor IX variant with higher potency than factor IX Padua.
Nair N; De Wolf D; Nguyen PA; Pham QH; Samara-Kuko E; Landau J; Blouse GE; Chuah MK; VandenDriessche T
Blood; 2021 May; 137(21):2902-2906. PubMed ID: 33735915
[TBL] [Abstract][Full Text] [Related]
19. FIXing postinfusion monitoring: Assay experiences with N9-GP (nonacog beta pegol; Refixia
Ezban M; Hermit MB; Persson E
Haemophilia; 2019 Jan; 25(1):154-161. PubMed ID: 30664825
[TBL] [Abstract][Full Text] [Related]
20. Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variants.
Samelson-Jones BJ; Finn JD; Raffini LJ; Merricks EP; Camire RM; Nichols TC; Arruda VR
Blood Adv; 2021 Mar; 5(5):1324-1332. PubMed ID: 33656538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
